WO2000003753A3 - Microdisperse drug delivery systems - Google Patents

Microdisperse drug delivery systems Download PDF

Info

Publication number
WO2000003753A3
WO2000003753A3 PCT/US1999/015781 US9915781W WO0003753A3 WO 2000003753 A3 WO2000003753 A3 WO 2000003753A3 US 9915781 W US9915781 W US 9915781W WO 0003753 A3 WO0003753 A3 WO 0003753A3
Authority
WO
WIPO (PCT)
Prior art keywords
microdisperse
drug delivery
delivery systems
compositions
fluids
Prior art date
Application number
PCT/US1999/015781
Other languages
French (fr)
Other versions
WO2000003753A2 (en
Inventor
Siva Narayan Tallavajhala
Original Assignee
Em Ind Inc
Siva Narayan Tallavajhala
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Em Ind Inc, Siva Narayan Tallavajhala filed Critical Em Ind Inc
Priority to CA002302735A priority Critical patent/CA2302735A1/en
Priority to DE1015046T priority patent/DE1015046T1/en
Priority to EP99933952A priority patent/EP1015046A2/en
Priority to JP2000559887A priority patent/JP2002520377A/en
Priority to AU49892/99A priority patent/AU4989299A/en
Publication of WO2000003753A2 publication Critical patent/WO2000003753A2/en
Publication of WO2000003753A3 publication Critical patent/WO2000003753A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods and compositions relating to microdispersion formulations for enhanced bioavailability of therapeutic agents are disclosed. Microdispersions of the compositions of the invention are formed upon contact with aqueous fluids, including physiologic fluids.
PCT/US1999/015781 1998-07-14 1999-07-14 Microdisperse drug delivery systems WO2000003753A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002302735A CA2302735A1 (en) 1998-07-14 1999-07-14 Microdisperse drug delivery systems
DE1015046T DE1015046T1 (en) 1998-07-14 1999-07-14 MICRODISPERSION ADMINISTRATION SYSTEM FOR MEDICINAL PRODUCTS
EP99933952A EP1015046A2 (en) 1998-07-14 1999-07-14 Microdisperse drug delivery systems
JP2000559887A JP2002520377A (en) 1998-07-14 1999-07-14 Microdispersed drug delivery system
AU49892/99A AU4989299A (en) 1998-07-14 1999-07-14 Microdisperse drug delivery systems

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9276798P 1998-07-14 1998-07-14
US60/092,767 1998-07-14

Publications (2)

Publication Number Publication Date
WO2000003753A2 WO2000003753A2 (en) 2000-01-27
WO2000003753A3 true WO2000003753A3 (en) 2000-05-04

Family

ID=22235064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/015781 WO2000003753A2 (en) 1998-07-14 1999-07-14 Microdisperse drug delivery systems

Country Status (8)

Country Link
EP (1) EP1015046A2 (en)
JP (1) JP2002520377A (en)
CN (1) CN1273526A (en)
AU (1) AU4989299A (en)
CA (1) CA2302735A1 (en)
DE (1) DE1015046T1 (en)
WO (1) WO2000003753A2 (en)
ZA (1) ZA200001010B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865695B2 (en) 2009-01-08 2014-10-21 Lipocine Inc. Steroidal compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
JP2004536026A (en) 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ，インコーポレーティッド． Pharmaceutical formulations containing paclitaxel, its derivatives, and pharmaceutically acceptable salts
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
FR2833842B1 (en) * 2001-12-21 2004-02-13 Aventis Pharma Sa PHARMACEUTICAL COMPOSITIONS BASED ON AZETIDINE DERIVATIVES
EP1498143A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
EP1498122A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid systems containing azetidine derivatives
EP1713442A1 (en) * 2004-01-30 2006-10-25 Pfizer Italia S.r.l. Semisolid matrix pharmaceutical formulations
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
FR2873585B1 (en) * 2004-07-27 2006-11-17 Aventis Pharma Sa NEW GALENIC FORMULATIONS OF ACTIVE PRINCIPLES
GB2451811A (en) 2007-08-09 2009-02-18 Ems Sa Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
CN101827585A (en) * 2007-10-19 2010-09-08 雅培股份有限两合公司 Solid dispersion product containing N-aryl urea-based compound
US9402812B2 (en) 2009-09-23 2016-08-02 Indu JAVERI Methods for the preparation of liposomes
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865695B2 (en) 2009-01-08 2014-10-21 Lipocine Inc. Steroidal compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9205057B2 (en) 2010-11-30 2015-12-08 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9480690B2 (en) 2010-11-30 2016-11-01 Lipocine Inc. High-strength testosterone undecanoate compositions
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters

Also Published As

Publication number Publication date
AU4989299A (en) 2000-02-07
JP2002520377A (en) 2002-07-09
DE1015046T1 (en) 2001-02-08
ZA200001010B (en) 2000-10-16
EP1015046A2 (en) 2000-07-05
WO2000003753A2 (en) 2000-01-27
CN1273526A (en) 2000-11-15
CA2302735A1 (en) 2000-01-27

Similar Documents

Publication Publication Date Title
WO2000003753A3 (en) Microdisperse drug delivery systems
WO2000041681A3 (en) MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN α-ANTAGONIST
WO2002070438A3 (en) Compositions for delivering bisphosphonates
WO2004043363A3 (en) Protein-stabilized liposomal formulations of pharmaceutical agents
WO2000007979A3 (en) Compounds and compositions for delivering active agents
CA2386690A1 (en) Pharmaceutical tramadol salts
MXPA05002814A (en) Formulation for lipophilic agents.
EP1246608A4 (en) Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
MXPA03007712A (en) Pharmaceutical salts.
AU3076700A (en) 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
PT1441705E (en) Solid, stabilized, prompt- and/or modified-release therapeutical systems for the oral administration of liquid active principles, excipients or foodstuffs
GB0126151D0 (en) Administration of medicaments by vaporisation
IL157940A0 (en) Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient
AU2002364893A1 (en) Delivery of medicaments to the nail
ZA200200743B (en) Preserved pharmaceutical formulations.
WO2003028696A8 (en) Compositions for delivery of drug combinations
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
AU2001234114A1 (en) Drugs containing combined active ingredients
WO2002015959A3 (en) Compounds and compositions for delivering active agents
MXPA03007903A (en) Highly flexible transdermal therapeutic system having nicotine as active substance.
ZA200007415B (en) Amino acid derivatives and drugs containing the same as the active ingredient.
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance
WO2001037818A3 (en) Medicament and combination of compatible medicaments
AU1556601A (en) 1,3,4-oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99801129.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2302735

Country of ref document: CA

Ref document number: 2302735

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2000 559887

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2000/00014/MU

Country of ref document: IN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 49892/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999933952

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 1999933952

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09486220

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999933952

Country of ref document: EP